RAP - The Next Phase, page-2161

Trials will last 3-4 months, but FDA approval will be sooner. It will take a shorter period of time (approximately 3/4 weeks) to gather enough clinical data for the more common respiratory illnesses such as pneumonia and bronchitis, then a submission will be made for each disease - all whilst more data for other illnesses are being collected.

ResApp will have deals lined up before FDA approval, once initial approvals are granted revenue will start rolling in within weeks. Management have active discussions underway with all major US Telehealth players.

The inclusion of other diseases will be done through a software update or similar system.

If ResApp start US trials this week as stated in the article, that will be a major milestone ticked. Big things are around the corner!